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ABSTRACT
Background. Tuberculosis (TB) has a high prevalence in Brazil. The scenario of liver
transplantation (LT) creates challenges: atypical presentation, treatment hepatotoxicity,
and increased mortality. The majority of TB cases after transplantation represent
reactivation of latent infections; therefore, prophylaxis (PX) plays a major role. The aim
of this study was to evaluate the benefits of PX after LT based on a pretransplantation
tuberculin test (TT) in an endemic area.
Methods. Retrospective analysis of medical data from 376 adult cirrhotic patients
undergoing OLT from 2001 to 2009.
Results. Among 191 selected patients, 137 (71%) showed a pretransplant TT including
41 (30%) with a TT 5 mm. The 17 (40%) of these patients who were prescribed PX did
not experience TB. Prophylaxis was discontinued in 5 patients (20%) owing to suspicion of
hepatotoxicity (medium serum alanine transaminase 175 U/L). In the group without PX,
we diagnosed 1 case of pulmonary TB. The overall prevalence of anergic patients in the
cirrhotic phase was 65% and prevalence of TB 1%.
Conclusions. The prevalence of TB was similar to that reported in the literature, but
positivity to TT was higher (34% vs 25%), possibly because of the endemicity of the area.
There was a lower prevalence of extrapulmonary disease and no mortality. No patient
undergoing PX with isoniazid, although incomplete due to suspicion of hepatotoxicity
displayed TB. One patient without PX was affected by TB. The drug was effective but not
always safe.
s
aTuberculosis is a major public health problem world-wide, especially in developing countries. In Brazil
there are 50 million infected people, with 85,000 new
cases per year (corresponding to an incidence of 47/
100,000 inhabitants) and 6,000 deaths per year.1 Thus
Brazil is among the 22 countries that include 80% of all
tuberculosis cases.1 Rio de Janeiro is the Brazilian state
with the highest incidence and mortality rates of tuber-
culosis. In Rio de Janeiro city, in 2006, the 5,749 new
cases of tuberculosis corresponded to an incidence of
93.7/100,000 inhabitants and a mortality rate of 5.4/
100,000 inhabitants.3 The chaotic urbanization, the mas-
sive urban population (96.4% in 2000, the country’s
highest rate) and the deficiencies in public health care
are the possible reasons for these high rates.1
At present, there is sufficient evidence of the efficacy of
current drugs. In studies of drug resistance, Brazil shows a
low rate of primary resistance; apparently this is not respon-
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Transplantation Proceedings, 43, 199–202 (2011)ible for the high mortality rates. Therefore, tuberculosis is
n avoidable cause of death.2
The emergence of acquired immunodeficiency syn-
drome elevated tuberculosis as an opportunistic disease.
At the same time, improved immunosuppressive drugs in
the transplantation scenario created a new pool of sus-
ceptible patients. The prevalence of tuberculosis ranges
from 0.5% to 11% among patients undergoing a solid
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200 AGOGLIA, BALBI, HALPERN ET ALorgan transplantation, depending on the endemicity of
the area.4 After liver transplantation (LT), the rate
anges from 0.9 to 2.3%.5,8 A recent meta-analysis re-
vealed values of up to 6%, with an annual incidence of
about 450/1,000,000 in habitants.6 The peak incidence
occurs in the fourth month after liver transplantation,4,12
with more than one-half of the patients showing an
extrapulmonary presentation6,13 with the risk for graft
infection. The challenges that delay diagnosis consist of
atypical presentations and the high frequency of
coinfections.12
The mortality rate can reach 40%5–7,9,10 despite treat-
ent; without treatment it is 100%.6 Predictors of mortality
have been recently suggested to be symptoms-diagnosis
interval 1 month, treatment with 3 drugs, and absence
of therapy.6
Although most LT candidates are anergic on the
tuberculin test (TT) because of immunodepression due
to cirrhosis, positivity (TT 5 mm) occurs among up to
25%.5 This subgroup of patients shows a 4-fold risk for
tuberculosis after LT,5,12 because in most cases this state
represents “latent disease” (LTBI) rather than previous
vaccination.10,12 These transplant recipients are more
susceptible to reactivation of the latent disease after
immunossuppression.
Because TT underestimates LTBI among cirrhotic pa-
tients, an earlier TB diagnosis (not adequately treated), a
recent high-risk contact, or a chest radiograph suggesting
past infection help to identify subjects with LTBI. Tuber-
culosis in organ transplant recipients may also develop,
albeit much less commonly, either after a new exposure or
by transmission from an organ donor.
Prophylaxis (PX) for 9 months with isoniazid is indicate
in LTBI, but there are reports of 6-month treatment, as
currently used in Brazil.6,8,12 It is recommended to start as
oon as liver function and liver enzymes are stable,6 but
within the first 6 months after LT. Not only TT 5 mm
indicates PX, but also an abnormal thoracic image,10 a
istory of incompletely treated tuberculosis, recipients from
iving donors with a TT 10 mm, and/or a recent high-risk
ontact.6
Many authors consider that the risk of isoniazid hepato-
toxicity in transplantation patients may be greater than the
benefit,10 as recently discussed in a large meta-analysis.6
Liver enzyme alterations after LT are generally due to acute
rejection episodes, reactivation of underlying disease (prin-
cipally viral hepatitis), vascular/biliary complications, or
opportunistic infections (such as cytomegalovirus). In these
cases, isoniazide may be a confounding variable; therefore,
clinical suspicion must be high.
Hepatotoxicity criteria are not well defined in the litera-
ture. Benito et al10 defined hepatotoxicity as a 5-fold
ncrease in serum aspartate-transaminase, improvement or
esolution after isoniazid withdrawal, and histologic fea-
ures of hepatitis on liver biopsy. They found a 17% rate of
atients who met criteria for hepatotoxicity; almost one-
alf of them showed alterations in liver enzymes.10 Drugsuspension rates were 6%6 to 42%,9 but multidrug regimens
did not appear to be a better choice.6
An alternative approach prescribe isoniazid chemopro-
phylaxis during the period of transplant candidacy. This
approach can prevent toxicity to the graft, but the tolera-
bility of isoniazid and the possibility of hepatotoxicity in
end-stage liver failure patients make this a frightful option.
Singh et al9 in 2002 and Jahng et al in 20078 reported series
f compensated cirrhotic patients (Child 6–8, average
odel for End-Stage Liver Disease 13). Both series noted
ood results, suggesting also the possibility of using rifam-
in which is commonly used in cholestatic patients for
ruritus, for 4 months as a safe prophylaxis. It should be
voided after LT, because it accelerates the metabolism of
mmunosuppressive drugs.8,12
Established disease, does not entail a focus on “risk
versus benefit” as does PX, but rather consideration of
which therapeutic regimen is more safe and efficient. The
most commonly used agents in Brazil—isoniazid, rifampin,
and pyrazinamide—are prescribed for 6 months but fre-
quently changed to other drugs such as ethambutol or
ofloxacin. In a recent meta-analysis of 139 treated patients,
Holty et al showed a high rate of hepatotoxicity (73%),
although the criteria for the diagnosis were not defined.
Thirty percent of subjects changed drugs or stopped treat-
ment6; the average time between starting treatment and
epatotoxicity was 3 months, and isoniazid was the most
epatotoxic drug.6 The literature has failed to identify
otable differences in the natural history or management of
B infections between live- and deceased-donor liver trans-
lantation cases.11 The aim of the present study was to
valuate prophylaxis after LT in an endemic area, based on
he pretransplantation TT.
METHODS
This retrospective study reviewed hospital records of patients who
underwent a deceased- or live-donor primary LT between 2001 and
2009. Exclusion criteria were: patients transplanted due to acute
liver failure, age 13 years at transplantation date, patients
deceased 6 months from the procedure and history of correctly
and fully treated tuberculosis or PX due to a high-risk contact. The
inclusion criterion for TT results before LT was induration 5 mm
in diameter at 48–72 hours after administration of tuberculin
intradermally. Furthermore, we included living-donor liver recipi-
ents from donors whose was TT 10 mm.
Patients with TT 5 mm or donor TT 10 mm underwent
administration of isoniazid after transplantation. Drug suspension,
mean alanine transaminase (ALT) at suspension, tuberculosis
diagnosis, and death were the endpoints. Patients in whom PX was
not performed, despite these indications, were also analyzed for
group comparisons. We secondarily evaluated the response to TT
among the whole study population.
RESULTS
We performed 376 LTs from 2001 to 2009. The recipient
gender distribution was almost equal (52% male/48% fe-
male), with a median age of 38.4 years at transplantation.
The principal etiology was hepatitis C, followed by hepatitis
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PREVENTING TUBERCULOSIS IN LIVER TRANSPLANT RECIPIENTS 201C and hepatocellular carcinoma, corresponding in aggre-
gate to 33% of cases. After applying the exclusion criteria,
191 patients were considered for the study. Fifty-four
patients (29%) had not had a TT performed during the
candidacy period. The other 137 patients (71%) had a
pretransplant TT: the majority were anergic (90 patients,
66%), 6 patients showed a TT 5 mm (4%), and 41
(30%) 5 mm, thereby meeting one of the inclusion
criteria (Fig 1).
Among this study group, 41% had undergone 6 months
of PX with isoniazid (300 mg daily) started within the first
6 months after transplantation. Three other patients who
were selected as the study group because their donors had
a TT 10 mm received the same prophylaxis. No patient
received it because of an abnormal thoracic and image a
history of untreated tuberculosis. Almost 60% of the group
had no PX even though it was indicated.
Analyzing the principal outcome, no patient (including
those with drug discontinuation) in the PX group displayed
tuberculosis after transplantation, with a median follow-up
of 5.3 years.
No standard criteria were used to define hepatotoxicity.
The median serum ALT value at the time of the drug
suspension was 175 U/L, namely, a 3-fold increase above
the normal value. After a median of 3 months of isoniazid
use, PX was discontinued in 5 patients (20%).
Among the group not undergoing PX, there was 1 case of
pulmonary tuberculosis. This patient did not received PX,
principally owing to an acute rejection episode in the first
months after LT. The diagnosis was established at 2 years 2
months after LT. He underwent the standard treatment
(rifampin  isoniazid  pyrazinamide) for 9 months with-
out major complications.
The other 2 tuberculosis cases occurred in a patient who
was previously anergic and a patient with unknown TT
status. The former experienced a pleural-pulmonary form
at 1 year 4 months after transplantation; standard treatment
was suspended within 1 month owing to hepatotoxicity,
requiring a 1-year course of a alternative regimen of
streptomycin, ethambutol, and ofloxacin. The patient with
unknown TT status had pulmonary involvement at 10
months after transplantation, also with pleural involvement.
Owing to preexistent hepatic injury from cytomegalovirus
infection as well as biliary stenosis and an acute rejection
episode, the subject received the alternative regimen for 1
year.
The overall prevalence of TB among the transplanted
population was 1%. If exclusion due to death before 6
months after transplantation is not considered, the overall
prevalence among cirrhotic phase of TT 5 mm was 30%,
with 66% anergic and 4% TT 5 mm.
DISCUSSION
Limitations to our study exist. It was not a prospective
controlled study. The evaluation of the enzyme profiles
during PX was only partial. No biopsy was undertaken in aajority of patients with enzyme elevations. In contrast, we
ave reported many more patients tested with TT before
T compared with the literature (71% vs 47%). The
ositivity to TT among our sample was higher than in the
iterature (34% vs 25%), possibly because of the endemicity
f the geographic area. Although observations regarding
he stage of liver disease and the correlation with the grade
f immune response were not possible, we can, however,
onfirm that the poor immune responses among cirrhotic
atients in general can result in false negative tests. Our
ample included 1 TT-anergic case among 90 anergic
atients who developed TB. Curiously, a patient with a
istory of previously treated tuberculosis was also anergic.
uantiferon TB Gold, an interferon-release assay, does not
ppear to overcome the shortcomings associated with TT,
ecause it also measures the cellular immune response to
ycobacterium tuberculosis.12 Our prevalence of tuberculo-
is was similar to the literature, despite the fact that we are
n an endemic area. We had a lower prevalence of extrapul-
onary disease and no mortality. The prevalence of tuber-
ulosis in our study was similar to another Brazilian study,
lthough the latter comes from a less endemic Brazilian
tate.13
No patient undergoing PX with isoniazid, although in-
complete due to hepatotoxicity, displayed tuberculosis. The
drug was effective but not always safe. The rate of interrup-
tion due to hepatotoxicity was similar to the literature,9 but
igher than that in a recent meta-analysis.6 Nevertheless,
the median ALT serum level at suspension was lower than
that used in the literature.10
Among the patients with an indication for but not
undergoing PX, 1 experienced tuberculosis. Although it was
not statistically significant, owing to the sizes of the groups,
there was another case of tuberculosis in whom we did not
know the TT status.Fig 1. Distribution of tuberculosis cases.
202 AGOGLIA, BALBI, HALPERN ET ALAll cases of tuberculosis were diagnosed after 1 year
after LT, contradicting the 4th-month occurrence peak. In 1
case, the diagnosis was established2 years after transplan-
tation, suggesting an exogenous infection. In 50% of cases,
there was a history of an acute rejection episode, with
aggressive imunosuppression and coinfection, confirming
risk factors cited in the literature.12 The tolerability of LT
patients to standard treatment is poor; the majority of
patients had to change their drug regimen.
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